Clario, a leading provider of endpoint data solutions for clinical trials, announced the acquisition of NeuroRx Research Inc. and its group companies (NeuroRx), a transaction that will enable NeuroRx to expand its reach, increase innovation and broaden its impact on drug development.

NeuroRx is an imaging provider with unparalleled expertise in diseases impacting the central nervous system, and Clario is a leading provider of endpoint data solutions to the clinical trials industry. 

Norton Rose Fulbright Canada acted for NeuroRx with a team that includes Eric Stevens, Julia Godolphin, Sophie Doyle, Elliott Delage, Derek G. Chiasson, Michel Gosselin-Trépanier, Nikita Stepin, Brian Chau, Francis Champagne, and Mikaela Mailly.